Good Company

IDEXX Grows Revenue 10 Percent in Q3 and Raises Its 2026 Outlook on Diagnostics Demand

The Westbrook, Maine diagnostics leader reached $1.214 billion in third quarter revenue, placed more than 1,900 inVue Dx analyzers, and lifted its full year revenue and earnings guidance while trimming its margin outlook for acquisition costs.

By Good Company Editorial Desk

IDEXX Laboratories logo

The News

IDEXX Laboratories reported third quarter 2026 results on October 30 for the quarter ended September 30, and the headline is growth with a guidance raise attached. Revenue reached $1,214 million, up 10 percent as reported and organically, driven by Companion Animal Group growth of 10 percent on both measures, according to the company release. Earnings per diluted share were $4.01, up 18 percent as reported and 22 percent on a comparable basis.

The engine was recurring diagnostics. Companion Animal Group Diagnostics recurring revenue grew 11 percent as reported and organically, including 13 percent reported and 14 percent organic growth in international regions and 10 percent reported and organic growth in the United States, a pace the company says outpaced sector growth levels. IDEXX VetLab consumables revenue grew 14 percent as reported and 15 percent organically, supported by net new customer growth, an 11 percent expansion of the global premium instrument installed base, higher utilization from recent product launches, and net price gains. Reference laboratory diagnostic and consulting services revenue grew 10 percent, while rapid assay products rose just 1 percent, with price benefits offsetting lower testing volumes.

Placement volume told the forward story. Capital instrument revenue was flat, but IDEXX placed more than 1,900 inVue Dx analyzers during the quarter. Veterinary software, services and diagnostic imaging systems revenue grew 11 percent as reported and 10 percent organically, helped by diagnostic imaging installations led by ImageVue DR50 Plus. Water revenue grew 8 percent and Livestock, Poultry and Dairy revenue grew 3 percent.

President and Chief Executive Officer Mike Erickson tied the quarter to innovation and to a software deal. "IDEXX delivered exceptional third quarter results, reflecting strong commercial execution and momentum from our innovation-driven growth strategy," Erickson said in the release. "Innovations like IDEXX inVue Dx with FNA, and IDEXX Cancer Dx becoming a multi-cancer panel, are helping practices detect disease earlier and work more efficiently. In software, we advanced our capabilities with the acquisition of CoVet, an AI clinical assistant that supports veterinary team productivity and diagnostics utilization, creating more value for our customers and shareholders."

On the back of the quarter, IDEXX raised its full year 2026 revenue guidance to $4,741 million to $4,767 million and raised its earnings per share outlook to $14.96 to $15.16. It lowered its full year operating margin outlook to 32.1 percent to 32.3 percent, a change the company says includes acquisition related impacts.

Why It Matters

First, this is a demand signal for veterinary care at a time when cost pressure on owners has been a recurring worry. IDEXX says same store volume growth, net customer gains, and premium installed base expansion drove double digit recurring diagnostics growth. That combination points to clinics testing more, not only charging more, even though price realization helped. For an industry that has spent two years debating whether owners would delay care, a 10 percent US recurring diagnostics gain is concrete evidence that core testing held up in the quarter.

Second, the quarter shows the installed base model working in plain sight. More than 1,900 inVue Dx placements in one quarter did not lift capital instrument revenue, which was flat, but placements expand the base that uses consumables over time. VetLab consumables, the recurring line tied to that base, grew 15 percent organically. The lesson is in the sequence: place the analyzer, then earn on utilization, reference lab volume, and software around it.

Third, IDEXX is buying workflow, not just tests. The CoVet acquisition, described by the company as an AI clinical assistant, adds only about $5 million to expected 2026 revenue in the updated guidance. Its stated value is productivity for veterinary teams and higher diagnostics utilization. That is a different kind of deal from a test menu expansion: it aims to remove friction in the clinic day so more diagnostics actually happen.

Fourth, the margin trim matters because it shows the cost of that strategy. Gross margin rose to 62.9 percent and operating margin rose to 33.1 percent in the quarter, yet full year margin guidance moved down. Operating expenses rose 10 percent as the company expanded commercial capabilities and advanced its innovation agenda while absorbing acquisition impacts, including transaction related costs. Growth is strong, and IDEXX is choosing to spend into it.

The Numbers

  • IDEXX Q3 2026 revenue: $1,214 million, up 10 percent as reported and organically (IDEXX release)
  • Q3 earnings per diluted share: $4.01, up 18 percent as reported and 22 percent on a comparable basis; comparable EPS was $3.96 (IDEXX release)
  • Companion Animal Group revenue growth: 10 percent as reported and organically (IDEXX release)
  • CAG Diagnostics recurring revenue: up 11 percent as reported and organically; $967.4 million as reported in secondary coverage of the release; US up 10 percent organically, international up 14 percent organically (IDEXX release; Middle News)
  • IDEXX VetLab consumables: up 14 percent reported and 15 percent organic; global premium instrument installed base expanded 11 percent (IDEXX release)
  • Reference laboratory diagnostic and consulting services: up 10 percent as reported and organically (IDEXX release)
  • Rapid assay products: up 1 percent, with price benefits offsetting lower testing volumes (IDEXX release)
  • InVue Dx placements: more than 1,900 in the quarter; capital instrument revenue was flat (IDEXX release)
  • Veterinary software, services and diagnostic imaging: up 11 percent reported and 10 percent organic, led by ImageVue DR50 Plus installations (IDEXX release)
  • Water: up 8 percent; Livestock, Poultry and Dairy: up 3 percent (IDEXX release)
  • Gross profit: up 12 percent; gross margin 62.9 percent, up 110 basis points as reported; operating margin 33.1 percent, up 100 basis points as reported (IDEXX release)
  • Full year 2026 revenue guidance, updated: $4,741 million to $4,767 million, reported growth of 10.1 percent to 10.8 percent; midpoint raised $32 million, including $5 million related to CoVet (IDEXX release)
  • Full year organic growth outlook, updated: 9.3 percent to 10.0 percent, up 0.6 percent at midpoint (IDEXX release)
  • Full year EPS outlook, updated: $14.96 to $15.16, up $0.25 at midpoint, for reported growth of 15 percent and comparable growth of 16 percent (IDEXX release)
  • Full year operating margin outlook, lowered: 32.1 percent to 32.3 percent, for expansion of 50 to 70 basis points, down from 70 to 90 basis points previously (IDEXX release)
  • Headquarters and scale: headquartered in Maine, about 11,000 employees, customers in more than 175 countries and territories (IDEXX release)

What It Means For You

If you run a veterinary practice, read the placement number as a competitive signal. Clinics around you are adding point of care capacity that promises faster answers, including fine needle aspirate work through inVue Dx with FNA and broader cancer testing through Cancer Dx as a multi-cancer panel, in the company's description. Ask your own team a simple question this week: where do cases still wait on an outside result when an in clinic option now exists, and what does that wait cost in follow up visits and client confidence?

If you sell to clinics, sell utilization, not equipment. IDEXX's flat capital revenue and 15 percent organic consumables growth show where the money repeats. Bring a utilization plan with any placement pitch: staff training, test menu defaults, reminder workflows, and a 90 day usage target. A box placed without a usage plan is a future churn risk, for you and for the clinic.

If you build software for practices, note what IDEXX chose to acquire. CoVet contributes little guided revenue this year, yet IDEXX highlighted it in the CEO quote alongside its flagship analyzers. The bet, as the company frames it, is that an AI clinical assistant that lifts team productivity will also lift diagnostics utilization. Position your product the same way if you can prove it: time saved per case, and what that time converts into.

If you run a pet health brand outside diagnostics, take the demand read seriously but do not overread it. Recurring diagnostics grew in the US and faster internationally, and management said the US pace outpaced sector growth. That supports continued investment in preventive and early detection positioning. It does not prove every discretionary category is recovering, and rapid assay at 1 percent growth is a reminder that volume can soften inside an otherwise strong quarter.

What To Watch

Watch whether the inVue Dx placement pace converts into sustained consumables growth in the fourth quarter and into 2027. That conversion is the real test of the installed base story, not placement volume alone.

Watch CoVet integration. IDEXX has guided only about $5 million of 2026 revenue from the deal and has absorbed acquisition impacts in its margin outlook. Look for concrete disclosure on adoption inside practices and on whether software growth, already up 10 percent organically, accelerates.

Watch the January 18, 2027 session at VMX in Orlando, where IDEXX says it will highlight its next point of care analyzer, IDEXX MultiCue Dx, with a webcast for investors and analysts. That event should clarify how much of the next growth leg depends on a new platform versus the current installed base.

Watch margins. The full year outlook now assumes 50 to 70 basis points of expansion instead of 70 to 90. If commercial and innovation spending stays at the third quarter pace, the question for 2027 guidance will be whether IDEXX protects margin or keeps buying growth.

Sources

  • IDEXX Laboratories, Third Quarter 2026 Results, Business Wire, October 30, 2026: https://www.businesswire.com/news/home/20261030555612/en/IDEXX-Laboratories-Announces-Third-Quarter-Results
  • Middle News, IDEXX Turns Analyzer Placements Into a 2026 Guidance Lift, November 2, 2026: https://www.middle.news/articles/2026/11/02/idexx-lifts-2026-guidance-as-diagnostics-demand-drives-a-powerful-third-quarter